A new multi-omics study has identified a promising noninvasive way to detect a dangerous liver complication in the most fragile newborns, before the condition is conventionally diagnosed. By combining stool microbiome sequencing, fecal and urinary bile acid measurements, and urinary metabolomics, researchers found that sulfated bile acids excreted in urine strongly signal the onset of parenteral nutrition-associated cholestasis (PNAC) in very preterm infants. A composite score built from the top three urinary bile acids achieved an area under the receiver operating characteristic curve (AUC) of 0.950, outperforming every other molecular layer examined in the study.
PNAC is a major complication in very preterm infants, defined as those born before 30 weeks of gestation, who must receive prolonged parenteral nutrition — intravenous feeding that bypasses the gut. The condition involves a disruption of bile flow, leading to an accumulation of conjugated bilirubin in the blood, a state known as conjugated hyperbilirubinemia. The problem for clinicians is timing: by the time conjugated hyperbilirubinemia appears and a diagnosis can be made, liver injury is already established. Noninvasive biomarkers that reflect disturbances in the gut-liver axis have remained limited, leaving neonatal intensive care teams largely reactive rather than proactive.
The new research, published in the Journal of Translational Medicine, took a prospective cohort approach to this diagnostic gap. The study enrolled 81 very preterm infants receiving prolonged parenteral nutrition. Of these, 20 infants went on to develop cholestasis, while 61 served as age- and time-matched controls. Critically, urine and stool samples were collected during the period of parenteral nutrition exposure, predominantly at the time when PNAC occurred, allowing the researchers to capture the molecular landscape of the disease as it emerged rather than reconstructing it retrospectively.
The technological backbone of the study was a trio of complementary analytical platforms. Bile acids in urine and feces were quantified using ultra-performance liquid chromatography coupled with tandem mass spectrometry, a technique capable of resolving and measuring dozens of individual bile acid species at very low concentrations. Urinary metabolomics was performed using proton nuclear magnetic resonance spectroscopy, which provides an unbiased snapshot of small-molecule metabolism without requiring chemical labeling. Meanwhile, the gut microbiome was profiled through 16S ribosomal RNA sequencing, which identifies and quantifies bacterial taxa present in stool samples. Statistical associations and diagnostic performance were then evaluated using logistic regression and receiver operating characteristic analyses across all four data layers.
The results revealed that infants who developed cholestasis showed measurable alterations across every omics dimension examined — microbiome composition, fecal bile acid profiles, urinary bile acid concentrations, and urinary metabolite patterns. But the layers were not equally informative. Urinary bile acids demonstrated the strongest discriminatory performance of any single omics layer, a finding that carries both biological and practical significance. Among the standout molecules were sulfated bile acids, including taurolithocholic acid-3-sulfate and taurochenodeoxycholic acid-3-sulfate, both of which showed strong associations with disease risk.
Sulfation is a biochemical modification in which a sulfate group is attached to a bile acid molecule, increasing its water solubility and facilitating its excretion by the kidneys. When bile flow from the liver is impaired, bile acids that would normally be transported into the intestine instead accumulate in the liver and bloodstream, and the body compensates by shunting them toward alternative elimination routes, including sulfation and urinary excretion. This makes urinary sulfated bile acids a direct chemical readout of cholestasis: their presence in elevated amounts reflects bile that the liver could not excrete through its normal pathway. In preterm infants, whose immature livers and underdeveloped gut microbiomes already compromise bile acid handling, this signal appears particularly pronounced.
The comparative performance figures underline just how much stronger the urinary signal is. The composite urinary bile acid score achieved an AUC of 0.950, placing it in the range of clinically excellent diagnostic tests. The corresponding urinary metabolites scored 0.894, still strong but clearly behind. Fecal bile acids, which might seem the more intuitive measurement given that the gut is the normal destination of bile, reached only 0.734. Microbiome features alone performed worst, at 0.641 — barely better than chance. This hierarchy suggests that while microbial dysbiosis accompanies PNAC, it is the downstream chemical consequence of impaired bile flow, measurable in a simple urine sample, that carries the most diagnostic weight.
Beyond the diagnostic numbers, the study’s cross-omics analysis painted a coherent biological picture that the authors describe as an integrated gut-liver-urine framework. The analysis revealed coordinated associations linking gut microbial features to fecal bile acid profiles, fecal bile acids to urinary bile acid patterns, and urinary bile acids to broader urinary metabolite changes. In other words, the four molecular layers do not operate independently; they form a connected chain of cause and effect running from the intestinal ecosystem through hepatic bile acid metabolism to renal excretion. This systems-level view supports the growing recognition that PNAC is not simply a liver disease but a disorder of the entire gut-liver axis, in which the absence of enteral feeding, disrupted microbial bile acid metabolism, and immature hepatic transport converge.
The clinical implications could be substantial. A urine-based test would be uniquely suited to the neonatal intensive care setting, where infants are hooked to multiple lines and blood draws are rationed. Urine collection is painless, noninvasive, and can be repeated frequently, meaning a bile acid panel could in principle be monitored serially throughout the course of parenteral nutrition exposure, flagging rising risk before bilirubin levels climb. Earlier detection would open a window for interventions already known to influence PNAC outcomes, such as transitioning to enteral feeding more aggressively, initiating ursodeoxycholic acid therapy, or ruling out other causes of conjugated hyperbilirubinemia sooner.
The study also carries weight for what it says about translational methodology. Rather than betting on a single molecular class, the researchers benchmarked four omics layers head-to-head in the same cohort and under the same sampling conditions, an approach that transparently shows where the diagnostic signal actually lives. The finding that a metabolite class — urinary sulfated bile acids — beats both microbial sequencing and broader metabolomic screens is a reminder that in diseases driven by a specific biochemical bottleneck, targeted measurement of the bottleneck’s chemical fingerprint can outperform panoramic profiling.
Caveats remain. The cohort comprised 81 infants from a single center, and the findings will require external validation in larger and more diverse populations before a urinary bile acid panel can be adopted as a standard screening tool. The authors note the study was supported by grants from Chang Gung Memorial Hospital, Linkou, Taiwan, and the National Science and Technology Council, Taiwan, and was conducted under approval from the hospital’s Institutional Review Board with written informed parental consent for all enrolled infants. Still, with an AUC approaching 0.95 in a prospectively collected cohort, urinary sulfated bile acids have made a compelling case as the most robust biomarkers associated with PNAC in very preterm infants — and, if validated, may serve as the foundation for the first practical noninvasive test for cholestasis during parenteral nutrition exposure, potentially changing the management of one of the most feared complications of neonatal intensive care.
Subject of Research: Identification of urinary sulfated bile acids as noninvasive biomarkers of parenteral nutrition-associated cholestasis in very preterm infants through integrated multi-omics analysis
Subject of Research: Medicine
Article Title: Multi-omics analysis supports a gut-liver-urine framework and identifies urinary sulfated bile acids as biomarkers of parenteral nutrition-associated cholestasis
Article References: Chu, Y.-D., Lai, H.-H., Chen, M.-C., Chiang, M.-C., Yeh, C.-T., & Lai, M.-W. (2026). Multi-omics analysis supports a gut-liver-urine framework and identifies urinary sulfated bile acids as biomarkers of parenteral nutrition-associated cholestasis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08918-0
Image Credits: AI Generated
DOI: 10.1186/s12967-026-08918-0
Keywords: Parenteral nutrition-associated cholestasis, Preterm infants, Urinary bile acids, Sulfated bile acids, Biomarkers, Multi-omics, Gut-liver axis, Neonatal nutrition, Metabolomics, Gut microbiome, Cholestasis diagnosis
Cite Scienmag News
APA
MLA
Chicago
Daisy Hatcher. (September 4, 2026). Urinary sulfated bile acids flagged as biomarkers of nutrition-linked cholestasis. Scienmag. https://scienmag.com/urinary-sulfated-bile-acids-flagged-as-biomarkers-of-nutrition-linked-cholestasis/
Daisy Hatcher. “Urinary sulfated bile acids flagged as biomarkers of nutrition-linked cholestasis.” Scienmag, 4 September 2026, https://scienmag.com/urinary-sulfated-bile-acids-flagged-as-biomarkers-of-nutrition-linked-cholestasis/. Accessed 4 September 2026.
Daisy Hatcher. “Urinary sulfated bile acids flagged as biomarkers of nutrition-linked cholestasis.” Scienmag. September 4, 2026. https://scienmag.com/urinary-sulfated-bile-acids-flagged-as-biomarkers-of-nutrition-linked-cholestasis/
Copy citation
Download RIS
Tags: bile acid metabolism in preterm infantsbile acid profiling in newbornsbiomarkers for neonatal cholestasisearly biomarkers for neonatal liver injuryearly detection of liver injury in newbornsgut-liver axis disruption biomarkersgut-liver axis disruption in preterm infantsmicrobiome sequencing in preterm infantsmulti-omics analysis in neonatal healthmulti-omics approach in neonatal liver diseasenoninvasive detection of parenteral nutrition-associated cholestasisnoninvasive diagnostic biomarkersparenteral nutrition-associated cholestasis detectionpredictive modeling of cholestasis in preterm neonatespredictive models for neonatal cholestasispreterm infant liver complicationsstool microbiome and liver diseasestool microbiome and urinary biomarkers in neonatal careurinary metabolomics for early diagnosis of PNACurinary metabolomics in neonatal careurinary sulfated bile acidsUrinary sulfated bile acids as biomarkers for neonatal cholestasis
